{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(8)"],"submitter":["Larue M"],"pubmed_abstract":["<h4>Abstract</h4>To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-world cohort study were performed. Participants were adults with primary ITP, transient response to corticosteroids with/without intravenous immunoglobulin, and a platelet count of ≤30 × 109/L (or ≤50 × 109/L with bleeding). Patients in the RCT were randomized in arm A (prednisone × 3 weeks + dapsone for 12 months) or arm B (prednisone alone). The observational study involved dapsone initiation at 100 mg/d with standard follow-up. The primary end point was the response rate (platelet count of >30 × 109/L and ≥2× baseline level) at 52 weeks, with the response rate at 24 weeks and adverse events as secondary end points. The RCT enrolled "],"journal":["Blood advances"],"pagination":["1976-1983"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12018975"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of dapsone in adult primary immune thrombocytopenia."],"pmcid":["PMC12018975"],"pubmed_authors":["Larue M","Ebbo M","Duong TA","Rueter M","Bonnotte B","Lefrere F","Royer B","Boutin E","Languille L","Viallard JF","Lambotte O","Mahevas M","Moulis G","Michel M","Audia S","Galicier L","Godeau B","Canoui-Poitrine F","Comont T","Pan-Petesch B","Terriou L","Cheze S"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of dapsone in adult primary immune thrombocytopenia.","description":"<h4>Abstract</h4>To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-world cohort study were performed. Participants were adults with primary ITP, transient response to corticosteroids with/without intravenous immunoglobulin, and a platelet count of ≤30 × 109/L (or ≤50 × 109/L with bleeding). Patients in the RCT were randomized in arm A (prednisone × 3 weeks + dapsone for 12 months) or arm B (prednisone alone). The observational study involved dapsone initiation at 100 mg/d with standard follow-up. The primary end point was the response rate (platelet count of >30 × 109/L and ≥2× baseline level) at 52 weeks, with the response rate at 24 weeks and adverse events as secondary end points. The RCT enrolled ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-07-15T11:01:15.734Z","creation":"2026-07-03T03:15:57.814Z"},"accession":"S-EPMC12018975","cross_references":{"pubmed":["39874521"],"doi":["10.1182/bloodadvances.2024014939"]}}